IPIC Message Board - Msg: 2705881

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC

IPIC 0.0001000

0.0%

Aug 15 3:35 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Pancho Villa who wrote (872)	11/12/1997 12:37:00 PM
From: NeuroInvestment	Read Replies (1) of 1359

Re: the Khan study reported today in the WSJ: When one has such discrepant reports from various sources (32% vs 25% vs 8%) it raises questions regarding investigator bias (for or against the diet drugs) and the criteria used to define 'significance' in valvular anomalies. Keep in mind that the Framingham Heart Study people found 87% of their 3500 patients had some type of valvular leak, but stated that overall, only 6% were 'significant'. There is no clear consensus about the rating of subjectively evaluated echocardiograms. I have also reviewed more detailed info about what was presented in Cancun. In looking at that data, I consider it less negative than the way it was portrayed in the WSJ. One example: in reference to my previous comment on what is considered 'significant', only 13% of individuals using Redux alone had anything more than 'trace' aortic leakage, compared to 26% of those taking fen/phen, 22% taking Redux/phen (which raises a question of phentermine's contribution). Khan claims that only 1% of his control group had mild or worse leakage, yet the Framingham Heart Study population (a general population group) had 10.5% displaying mild or worse aortic leakage. A second example: aortic valve thickening has been another anomaly of concern: in Khan's study, patients on Redux alone had less thickening than the control group, far less than the fen/phen group. His comment that Redux appears equal to fen/phen in its negative effects appears unsupported by his own data. Another very recent obesity abstract from a research group in CA followed 100 obesity drug users (26 of whom were on Redux alone), 40% of the sample already had diagnosed cardiac disease. Monthly echocardiograms showed that over a 3-9 month followup, "none of the patients developed abnormalities in valve morphology." The AHP 1200 patient study will be a vital key to resolving this La Brea tar pit of contradictory data. NeuroInvestment

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next